)
)
)
DiaMedica Therapeutics
DiaMedica Therapeutics Inc. is a clinical-stage biopharmaceutical company developing novel treatments with primary focus on preeclampsia, fetal growth restriction, and acute ischemic stroke. DiaMedica’s lead candidate, DM199, is the first pharmaceutically active recombinant (synthetic) form of the KLK1 protein, an established therapeutic modality in Asia for ischemic stroke and other vascular disorders, and is now being advanced in clinical development to address the significant unmet needs in maternal-fetal health and stroke.
Address
MinnetonkaMN
United States
)
){kind=logo}
)
){kind=logo}
){kind=logo}
)
)
)
)